三個皮匠報告
政策庫
new
付費
搜索

Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況-行業數據

Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況
國內企 目前有 3個產品（創勝集團-TST001、奧賽康-ASKB589、明濟生物-M108）進入Ⅲ期，均屬于 ADCC 增強 單抗，早期的臨床有 和安全 表現出優于安斯泰來的 Zolbetuximab的結果，具備“Best-in-Class”的潛力。
其它 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?67KB 圖片尺寸：2302*2230
同報告圖片
 / 14
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第1頁
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
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第2頁
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
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第3頁
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
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第4頁
fCDlubTku70gfCDog4PnmYzlhajnkIPlj5Hnl4XkurrmlbDvvIjkuIfkurrvvIkgfCDog4PnmYzkuK3lm73lj5Hnl4XkurrmlbDvvIjkuIfkurrvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IDIwMjIgfCA5NyAgICAgICAgICAgICAgICAgICAgICAgfCAzNiAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjVFfCAxMDQgICAgICAgICAgICAgICAgICAgICAgfCAzOCAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMzBFfCAxMTkgICAgICAgICAgICAgICAgICAgICAgfCA0NCAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMzVFfCAxMzUgICAgICAgICAgICAgICAgICAgICAgfCA1MCAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwNDBFfCAxNTEgICAgICAgICAgICAgICAgICAgICAgfCA1NSAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwNDVFfCAxNjkgICAgICAgICAgICAgICAgICAgICAgfCA1OSAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwNTBFfCAxODQgICAgICAgICAgICAgICAgICAgICAgfCA2MiAgICAgICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaR2xvYmFsIENhbmNlciBPYnNlcnZhdG9yee+8jOmVv+axn+ivgeWIuOeglOeptuaJgA==
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第5頁
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第6頁
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第7頁
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第8頁
| Antibody Concentration (nM) | TST001 Mean Fluorescence Intensity | IMAB362-analog Mean Fluorescence Intensity | Isotype control Mean Fluorescence Intensity |
|-----------------------------|------------------------------------|--------------------------------------------|--------------------------------------------|
| 0                           | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                          |
| 10                          | 0                                  | 0                                          | 0                                         
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第9頁
fCBUIENlbGwgfCBDQVIgfCBDQVItVCBDZWxsIHwKfCAtLS0gfCAtLS0gfCAtLS0gfAp8IEEga2V5IGZpZ2h0ZXIgaW4gdGhlIGltbXVuZSBzeXN0ZW0gfCBBIHNwZWNpZmljIHJlY2VwdG9yIGlzIGFkZGVkIHRvIHRoZSBUIGNlbGwgfCBBIFQgY2VsbCB3aXRoIHRoZSBDQVIgYWRkZWQgaGVscHMgZmluZCBhbmQgZmlnaHQgc3BlY2lmaWMgY2VsbHMgfAoK6LWE5paZ5p2l5rqQ77yaQ1JPV04gQklPU0NJRU5DRSDlrpjnvZHvvIzplb/msZ/or4HliLjnoJTnqbbmiYA=
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第10頁
fCDnrYnnuqcgfCDmj4/ov7AgICAgICAgICB8IOWPjeW6lOaApyAgICAgICB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgMCAgICB8IOaXoOWPjeW6lOaApyAgICAgfCBObyByZWFjdGl2aXR5fAp8IDErICAgfCDlvLHlj43lupTmgKcgICAgIHwgV2VhayByZWFjdGl2aXR5fAp8IDIrICAgfCDkuK3nrYnlj43lupTmgKcgICB8IE1vZGVyYXRlIHJlYWN0aXZpdHl8CnwgMysgICB8IOW8uuWPjeW6lOaApyAgICAgfCBTdHJvbmcgcmVhY3Rpdml0eXwKCui1hOaWmeadpea6kO+8mk1lZFNjaSDmoaPmoYjvvIzplb/msZ/or4HliLjnoJTnqbbmiYA=
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第11頁
fCDoja/kvIEgICAgICAgfCDliJvog5zpm4blm6IgICAgICAgICAgICAgICAgICAgICAgIHwg5aWl6LWb5bq3ICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18Cnwg5Lqn5ZOBICAgICAgIHwgT3NlbmF0YW1hYiAoVFNUMDAxKSAgICAgICAgICAgIHwgQVNLQjU4OSAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IOivlemqjOi/m+WxlSAgIHwgSUlJ5pyfICAgICAgICAgICAgICAgICAgICAgICAgICB8IElJSeacnyAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg6K+V6aqMIElEICAgIHwgTkNUMDQ0OTUyOTYoSUlh5pyfKSAgICAgICAgICAgICB8IE5DVDA0NjMyMTA4IChJL0lJ5pyfKSAgICAgICAgICAgICB8IE5DVDA1NjMyOTM5IChJYi9JSeacnykgICAgICAgICAgIHwKfCDmsrvnlpfnur8gICAgIHwgMUwgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMUwgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAxTCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg6K+V6aqM6K6+6K6hICAgfCDogZTlkIggQ0FQT1ggICAgICAgICAgICAgICAgICAgICB8IOiBlOWQiOe6s+atpuWIqeWwpOWNleaKlytDQVBPWCAgICAgICAgICAgfCDogZTlkIggQ0FQT1ggK0NBUFggICAgICAgICAgICAgICAgIHwKfCDor4TkvLDkurrmlbAgICB8IDQ5ICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDc5ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjQgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCA0NSAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg5YWl57uE5Z+657q/ICAgfCBDTEROMTguMisgKDEwJeiCv+eYpOe7huiDnuaYvuekuiAxKyBJSEMg5p+T6ImyKSB8IOS4jeS9nOimgeaxgiAgICAgICAgICAgICAgICAgICAgICAgICB8IENsYXVkaW4xOC4yKyAgICAgICAgICAgICAgICAgICAgIHwgQ0xETjE4LjIrICg0MCXogr/nmKTnu4bog57mmL7npLogMisvMyvohpwgSUhDIOafk+iJsikgfAp8IE9SUiAgICAgICB8IDU0LjgwJSAgICAgICAgICAgICAgICAgICAgICAgICB8IDU3JSAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNzkuMiUgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCA4MCUgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgRENSICAgICAgIHwgOTEuOSUgICAgICAgICAgICAgICAgICAgICAgICAgIHwgOTUuOCUgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAxMDAlICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg5Li05bqK5pWw5o2uLeacieaViOaApyB8IG1PUyDmnKrovr7liLDvvIwxMuS4quaciCBPUyDnjofkuLogODguOSUgfCDmnKrovr7liLAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IOacqui+vuWIsCAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5pyq6L6+5YiwICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IG1QRlMgICAgICB8IDE0ICjpooTorqEpICAgICAgICAgICAgICAgICAgICAgIHwgQ0xETjE4LjIg6auYL+S4reihqOi+vueahOS6mue7hOS4uiAxMi42ICB8IOacqui+vuWIsCAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5pyq6L6+5YiwICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IEhSICAgICAgICB8IDAuNDQzICjlr7nnhacgQ0xETjE4LjIg5p6B5L2OL+aXoOihqOi+vikgfCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IOW4uOingSBURUFFcyB8IChUUkFFKSDkvY7nmb3om4vnmb3ooYDnl4cgKDY3LjElKeOAgeaBtuW/gyAoNjMuNCUpIOWSjOWRleWQkCA1OS44JSB8ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg5Li05bqK5pWw5o2uLeWuieWFqOaApyB8IOS4pemHjSBURUFFcyDlkIzkuInogZTnlpfms5XlpKfkvZPkuIDoh7TvvIzlpKflpJrmlbDkuLogMS0yIOe6pyBUUkFFcyB8ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg4omlMyDnuqcgVEVBRXMgfCAoVFJBRSkg5Lit5oCn57KS57uG6IOe5YeP5bCRICgxMi4yJSnjgIHooYDlsI/mnb/orqHmlbDlh4/lsJEgKDkuOCUp44CB5oG25b+DICgzLjclKSDlkozlkZXlkJAgKDIuNCUpIHwgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8mkFTQ08sIEVTTU8sIOWFrOWPuOWumOe9kSwg5Yy76I2v6a2U5pa5LCDkuIHpppnlm60gSW5zaWdodCwg6ZW/5rGf6K+B5Yi456CU56m25omA
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第12頁
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
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第13頁
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
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第14頁
fCDnsbvlnosgICAgICAgfCDoja/nianlkI3np7AgICAgICAgICAgfCDnoJTlj5HmnLrmnoQgICAgICAgICAgICAgICAgICAgICAgIHwg5YWo55CD5pyA5b+r6L+b5bqmIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tfAp8IOWNleaKlyAgICAgICB8IFpvbGJldHV4aW1hYiAgICAgfCDlronmlq/ms7DmnaUgICAgICAgICAgICAgICAgICAgICAgIHwgSUnmnJ8gICAgICAgICB8Cnwg5Y2V5oqXICAgICAgIHwgQVNLQjU4OSAgICAgICAgICB8IEFza0dlbmUgUGhhcm1hICAgICAgICAgICAgICAgICB8IEkvSUnmnJ8gICAgICAgfAp8IOWNleaKlyAgICAgICB8IFRTVDAwMSAgICAgICAgICAgfCDliJvog5wgICAgICAgICAgICAgICAgICAgICAgICAgICB8IElJ5pyfICAgICAgICAgfAp8IOWNleaKlyAgICAgICB8IEJOVDE0MSAgICAgICAgICAgfCBCaW9OVGVjaCAgICAgICAgICAgICAgICAgICAgICAgfCBJL0lJ5pyfICAgICAgIHwKfCDljZXmipcgICAgICAgfCBMTS0xMDIgICAgICAgICAgIHwg56S85pawICAgICAgICAgICAgICAgICAgICAgICAgICAgfCBJL0lJ5pyfICAgICAgIHwKfCDljZXmipcgICAgICAgfCBNSUw5MyAgICAgICAgICAgIHwg5aSp5bm/5a6eICAgICAgICAgICAgICAgICAgICAgICAgIHwgSS9JSeacnyAgICAgICB8Cnwg5Y2V5oqXICAgICAgIHwgTkJMLTAxNSwgRkwtMzAxICB8IOefs+iNr+mbhuWbojsgRmxhbWUgQmlvc2NpZW5jZXMgICAgfCBJL0lJ5pyfICAgICAgIHwKfCBBREMgICAgICAgIHwgQ01HOTAxICAgICAgICAgICB8IOW6t+ivuuS6mibkuZDmma47IEFaICAgICAgICAgICAgICAgIHwgSUnmnJ8gICAgICAgICB8CnwgQURDICAgICAgICB8IExNLTMwMiAgICAgICAgICAgfCDnpLzmlrA7IFR1cm5pbmcgUG9pbnQgVGhlcmFwZXV0aWNzIHwgSUnmnJ8gICAgICAgICB8CnwgQURDICAgICAgICB8IFJDMTE4ICAgICAgICAgICAgfCDojaPmmIwgICAgICAgICAgICAgICAgICAgICAgICAgICB8IEkvSUnmnJ8gICAgICAgfAp8IEFEQyAgICAgICAgfCBTS0IzMTUgICAgICAgICAgIHwg56eR5Lym5Y2a5rOwOyDpu5jlhYsgICAgICAgICAgICAgICAgIHwgSS9JSeacnyAgICAgICB8CnwgQURDICAgICAgICB8IFNPLU4xMDIgICAgICAgICAgfCBTb3RpbyAgICAgICAgICAgICAgICAgICAgICAgICAgfCBJL0lJ5pyfICAgICAgIHwKfCBDQVItVCAgICAgIHwgTEIxOTA0ICAgICAgICAgICB8IOS8oOWlh+eUn+eJqSAgICAgICAgICAgICAgICAgICAgICAgfCBJL0lJ5pyfICAgICAgIHwKfCBDQVItVCAgICAgIHwgSU1DMDAyICAgICAgICAgICB8IOaYk+aFleWzsCAgICAgICAgICAgICAgICAgICAgICAgICB8IEkvSUnmnJ8gICAgICAgfAp8IENBUi1UICAgICAgfCBDVDA0MSAgICAgICAgICAgIHwg56eR5rWOICAgICAgICAgICAgICAgICAgICAgICAgICAgfCBJL0lJ5pyfICAgICAgIHwKfCBDTEROMTguMi9DRDMgfCBJQkkzODkgICAgICAgICAgfCDkv6Hovr4gICAgICAgICAgICAgICAgICAgICAgICAgICB8IElJ5pyfICAgICAgICAgfAp8IENMRE4xOC4yL0NEMyB8IEhCTTcwMjIsIEFaRDU4NjMgfCDlkozpk4I7IEFaICAgICAgICAgICAgICAgICAgICAgICB8IEkvSUnmnJ8gICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5Yy76I2v6a2U5pa577yM6ZW/5rGf6K+B5Yi456CU56m25omA
Claudin18.2單抗進入Ⅲ期試的產品與安斯泰來臨床數據對比情況_第15頁
所屬報告： 制藥行業聚焦Claudin18.2：國產企業領航全球研發藍海市場方興未艾-240715（23頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站